• Kalaris Therapeutics will present Phase 1a single-ascending-dose results for TH103 in treatment-naïve wet AMD patients on June 13, 2026.
• The data were previously presented at Retina World Congress 2026.
• The update highlights early clinical performance of TH103, the company’s lead retinal program, in a first-in-human setting.
• TH103 is being advanced into a Phase 1b/2 trial in neovascular AMD, supporting continued development toward longer-acting anti-VEGF therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606120800PRIMZONEFULLFEED9745960) on June 12, 2026, and is solely responsible for the information contained therein.